Evidence map›Paper›PMID 29789241›Full record

ArticleVaccine2018

Vaccines, inspiring innovation in health.

Sonia Pagliusi, Maureen Dennehy, Hun Kim, DCVMN AGM Organizing Committee

Open access · hybridAbstract readConference Proceedings
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature.Current treatment options in infectious diseases · 2021
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sonia PagliusiDCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn.net.
Maureen DennehyDCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: maureen@qast.co.za.
Hun KimVaccine Business Group, SK Chemicals, SK Chemicals Complex, 332, Pangyo-ro, Bundang-gu, Seongnam-si, 13493 Gyeonggi-do, South Korea. Electronic address: ebolakim@sk.com.
DCVMN AGM Organizing Committee
Developing Countries Vaccine Manufactures Network · CHSK Group (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report covers the topics of pandemics, epidemics and partnerships, including regulatory convergence initiatives, new technologies and novel vaccines, discussed by leading public and private sector stakeholders at the 18th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers' Network (DCVMN). Contributions of Gavi and the vaccine industry from emerging countries to the growing global vaccine market, by improving the supply base from manufacturers in developing countries and contributing to 58% of doses, were highlighted. The Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI) and others reported on new strategies to ensure speedy progress in preclinical and clinical development of innovative vaccines for future MERS, Zika or other outbreak response. Priorities for vaccine stockpiling, to assure readiness during emergencies and to prevent outbreaks due to re-emerging diseases such as yellow fever, cholera and poliomyelitis, were outlined. The role of partnerships in improving global vaccine access, procurement and immunization coverage, and shared concerns were reviewed. The World Health Organization (WHO) and other international collaborating partners provided updates on the Product, Price and Procurement database, the prequalification of vaccines, the control of neglected tropical diseases, particularly the new rabies elimination initiative, and regulatory convergence proposals to accelerate vaccine registration in developing countries. Updates on supply chain innovations and novel vaccine platforms were presented. The discussions enabled members and partners to reflect on efficiency of research & development, supply chain tools and trends in packaging technologies improving delivery of existing vaccines, and allowing a deeper understanding of the current public-health objectives, industry financing, and global policies, required to ensure optimal investments, alignment and stability of vaccine supply in developing countries.

Indexed as

Developing CountriesGlobal HealthImmunization ProgramsVaccinesDisease EradicationEpidemicsHumansInternational CooperationNeglected DiseasesPoliomyelitisPrivate SectorPublic HealthVaccination CoverageWorld Health OrganizationZika Virus InfectionVaccinesDeveloping countriesEpidemicProcurementStockpilingTechnologyVaccine manufacturing

Identifiers

PMID29789241
PMCPMC6238075
OpenAlexW2804465434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.